Hematologic Malignancies in the Era of Immunotherapy 2017
Symposium
Symposium

Hematologic Malignancies in the Era of Immunotherapy 2017

Clinician and Patient Perspectives

Not a member of My prIME? Join now for instant access.

Meeting Overview

This satellite symposium features key considerations for the current and future use of immunotherapy for the treatment of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Hodgkin lymphoma (HL), and multiple myeloma (MM). Compelling patient video snippets, faculty/participant discussion on practice challenges, and other unique features ensure an engaging learning experience.

Friday satellite symposium on Hematologic Malignancies in the Era of Immunotherapy: Clinician and Patient Perspectives preceding the 59th ASH Annual Meeting & Exposition

Date and Location

Friday, December 8, 2017
6.00 PM – 9.30 PM

Centennial I
Hyatt Regency Atlanta
265 Peachtree Street NE
Atlanta, Georgia 30303

Date/Time

Date/Time

Friday, December 8, 2017
6.00 PM – 9.30 PM

Location

Location

Atlanta, Georgia, United States

CME

CME

2.75 AMA PRA Category 1 Credits

Friday, December 8, 2017

6.00 PM Registration and dinner
6.30 PM Welcome and introduction
6.32 PM Segment One: Multiple Myeloma
Donna E. Reece, MD
Presegment knowledge/competence assessment
Patient video—multiple myeloma
How I treat relapsed multiple myeloma in the era of immunotherapy
My biggest practice challenge
Postsegment knowledge/competence assessment
7.12 PM Segment Two: Hodgkin Lymphoma
Andreas Engert, MD
Presegment knowledge/competence assessment
Patient video—Hodgkin lymphoma
How I treat relapsed Hodgkin lymphoma: Can it be cured?
My biggest practice challenge
Postsegment knowledge/competence assessment
7.52 PM Break
8.07 PM Segment Three: Chronic Myeloid Leukemia
Michael J. Mauro, MD
Presegment knowledge/competence assessment
Patient video—chronic myeloid leukemia
How I select and monitor treatment for chronic myeloid leukemia
My biggest practice challenge
Postsegment knowledge/competence assessment
8.47 PM Segment Four: Acute Myeloid Leukemia
Jorge Cortes, MD
Presegment knowledge/competence assessment
Patient video—acute myeloid leukemia
How I treat acute myeloid leukemia: The future of immunotherapy in leukemia
My biggest practice challenge
Postsegment knowledge/competence assessment
9.25 PM prIME Points™ and adjourn

    Chair

  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Faculty

  • Andreas Engert, MDUniversity Hospital of Cologne
    Cologne, Germany
  • Michael J. Mauro, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Donna E. Reece, MDPrincess Margaret Hospital
    Toronto, Ontario, Canada

Target Audience

This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Select optimal therapy approaches in collaboration with patients and families, considering clinical safety and efficacy data for current and emerging treatments and combinations for patients with AML, CML, relapsed HL, and relapsed/refractory MM
  • Develop side-effect monitoring and management approaches for current and emerging treatments for AML, CML, relapsed HL, and relapsed/refractory MM, including the immune-related adverse events associated with immunotherapies.
  • Identify promising clinical trials with novel therapies and combinations across the treatment landscape for AML, CML, relapsed HL, and relapsed/refractory MM
  • Engage patients and families in treatment decision making, by soliciting and incorporating their desires and goals for care

Support

This educational activity is supported by a grant from Bristol-Myers Squibb.

This event has passed.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Simulcast

This event has passed.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.